Cell and Gene Therapy World Market and Market Potential

Cell and Gene Therapy World Market and Market Potential presents the market in segments that provide an overview of disease epidemiology, market estimates and forecasts, and competitive summary of leading providers:

Cell and Gene Therapy Market Summary by Product Segment, 2021-2031 ($ millions) (Dermatological, Cardiovascular - Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total Market)
Cell and Gene Therapy Market Summary by Method, 2021-2031 ($ millions) (Cell Therapy, Gene Therapy, Total Market)
Cell and Gene Therapy Market Summary by Geographical Region, 2021-2031 ($ millions) (United States, Europe/European Union, Other Countries, Global Market)
Cell and Gene Therapy Market Summary for United States by Product Segment, 2021-2031 ($ millions) (Dermatological, Cardiovascular - Blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions, Total)
U.S. Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
Europe Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
Other Countries Cell and Gene Therapy Market, Distribution by Product Segment (Dermatological, Cardiovascular-blood, Oncology, Ophthalmic, Musculoskeletal, Other conditions), 2020 (%)
Estimated Cell and Gene Therapy Sales by Leading Competitor, 2021 Sales ($ millions)

Scope

The report examines developments in cell and gene therapy markets by condition/disorder, including principal products, trends in research and development, market breakdown of cell and gene therapies, regional market summary, and competitor summary.

The following conditions/disorders are covered:

Dermatology, including:

Dermatology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2026 and 2031 ($ millions) (Stem cells, Skin cells)
Dermatology Cell and Gene Therapy Market by General Indication, Estimated 2021, Projected 2026 and 2031 ($ millions) (Wound healing/treatment, Other indications [wrinkles, scar treatment])
Dermatology Cell and Gene Therapy Market by Country/Region, Estimated 2021, Projected 2026 and 2031 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
Dermatology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)

Cardiovascular and Blood Disorders, including:

Cardiovascular and Blood Disorders Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2026 and 2031 ($ millions) (Stem cells, Gene therapy, Other cell therapies; Stromal cells)
Cardiovascular and Blood Disorders Cell and Gene Therapy Market by General Indication, Estimated 2021, Projected 2026 and 2031 ($ millions) (Cardiac disorders, Vascular disorders, Blood disorders, Hypercholesterolemia)
Cardiovascular and Blood Disorders Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2026, 2030 ($ millions) (United States, Europe, S. Korea, Japan, ROW)

Oncology, including:

Oncology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2026 and 2031 ($ millions) (CAR-T, Cell immunotherapy, Gene therapy, Other cell therapy)
Oncology Cell and Gene Therapy Market by General Indication, Estimated 2021, Projected 2026 and 2031 ($ millions) (Blood cancers, Prostate cancer, Melanoma, Other cancers)
Oncology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2026, 2030 ($ millions) (United States, Europe, ROW)
Oncology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)

Ophthalmic Conditions, including:

Ophthalmology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2026 and 2031 ($ millions) (Stem cells, Gene therapy, Other cell therapy)
Ophthalmology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2026, 2030 ($ millions) (United States, Europe, Other countries)

Musculoskeletal Conditions and Disorders, including:

Musculoskeletal Cell Therapy Market, Estimated 2021 and Projected 2026 and 2031 ($ millions)
Musculoskeletal Cell and Gene Therapy Market by General Indication, Estimated 2021, Projected 2026 and 2031 ($ millions) (Cartilage Defect/Damage Repair, Bone Defect/Damage Repair, Others [tendon damage, osteoarthritis])
Musculoskeletal Cell and Gene Therapy Market by Country/Region, Estimated 2021, Projected 2026 and 2031 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)
Musculoskeletal Cell Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)

Other Conditions, including:

Other Conditions Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2026 and 2031 ($ millions) (Cell therapy, Gene therapy, Gene-modified cell therapy)
Other Conditions Cell and Gene Therapy Market by Country/Region, Estimated 2021, Projected 2026 and 2031 ($ millions) (United States, Europe/European Union, S. Korea, Other countries)

CHAPTER 1: EXECUTIVE SUMMARY
OVERVIEW
SCOPE AND METHODOLOGY MARKET
OVERVIEW AND POTENTIAL

Figure 1-1: Global Cell and Gene Therapy Market CAGR by Product Segment, 2021-2031

CHAPTER 2: INTRODUCTION TO CELL AND GENE THERAPY
INTRODUCTION

Cell Therapy
Table 2-1: Adult vs. Embryonic Stem Cells
Gene Therapy
Table 2-2: Somatic vs. Germ Line Gene Therapy
Viral Vector System and New Developments
Table 2-3: Selected Examples of Viruses in Gene Therapy
Figure 2-1: Viral Vector Use in Commercialized Cell and Gene Therapies
Non-viral Systems for Transporting Genes
Gene Editing

CELL AND GENE THERAPY: CHARACTERISTICS

Table 2-4: Cell Therapy vs Gene Therapy

STAFFING MANUFACTURING PROCESS FOR CAR-T

Leukapheresis
Activation
Transduction
Expansion

CELL AND GENE THERAPY MANUFACTURING PROCESSES

Table 2-5: Manufacturing Process Time for Select Autologous Cell and Gene Therapies (current and discontinued therapies)
Figure 2-2: Manufacturing Process Time for Select Autologous Cell and Gene Therapies (current and discontinued therapies)
Table 2-6: Selected Recent Viral Vector Company Expansion

COST

REIMBURSEMENT
LOGISTICS
MERGERS AND ACQUISITIONS

Table 2-7: Selected Company Mergers and Acquisitions in the Cell and Gene Therapy Market

PARTNERSHIPS, AGREEMENTS AND COLLABORATIONS

Table 2-8: Selected Company Partnerships, Agreements and Collaborations in the Cell and Gene
Therapy Market

FINANCING AND FUNDING DEALS

Table 2-9: Recent Cell and Gene Therapy Recent Financing Deals

REGULATORY DEVELOPMENTS

Figure 2-3: FDA Cell & Gene Therapy Percent of Projects with Orphan Drug and/or Fast Track
Status

Fast Track

Orphan Drug
Breakthrough Therapy
Accelerated Approval Priority Review

Table 2-10: Regulatory Actions and Guidelines for Cell and Gene Therapy by Select Country
Individualized Gene Therapy Approval Process

DEVELOPMENT AND PIPELINE OVERVIEW DEVELOPMENT PROGRESS

Figure 2-4: Global Cell and Gene Therapy Development Progress (phase I through phase III), as of January 2022
Figure 2-5: Global Cell and Gene Therapy Development Progress by Phase, as of January 2022

DEVELOPMENT BY CONDITION/DISORDER

Figure 2-6: Global Development of Cell and Gene Therapies by Target

GLOBAL PARTICIPATION IN CELL AND GENE THERAPY DEVELOPMENT

Figure 2-7: Global Development Activity of Cell and Gene Therapies by Country, as of January 2022

PHASE III DEVELOPMENT

Table 2-11: Phase III Development - Cell and Gene Therapies, Select Projects
Figure 2-8: Cell and Gene Therapy: Top 30 Developers (Phase I through Submission)

END USER

Hospitals
Research Institutes
Wound Care Centers
Cancer Centers

CHAPTER 3: CELL AND GENE THERAPY MARKETS IN DERMATOLOGY OVERVIEW

Table 3-1: Wound Prevalence by Type

MARKET OUTLOOK

Figure 3-1: Cell and Gene Therapy Markets in Dermatology, 2021-2031 ($ millions)

PRINCIPAL PRODUCTS

Adipocel
Apligraf
CureSkin
Dermagraft
Epicel
Grafix
Holoderm
Kaloderm
KeraHeal/KeraHeal-Allo
LaViv
Orcel
Quencell
RECELL
Rosmir
Stempeutics/Cutisera
StrataGraft
Stravix
TransCyte
Table 3-2: Cell and Gene Therapy in Dermatological Diseases and Disorders
Figure 3-2: Dermatology Cell and Gene Therapy Approvals by Year or Year Range, through 2021

TRENDS IN RESEARCH AND DEVELOPMENT

Table 3-3: Dermatology Cell and Gene Therapies in Development by Phase, January 2022 Data
Table 3-4: Dermatology Cell and Gene Therapies in Development by Method, January 2022 Data Phase III Development
Table 3-5: Select Dermatology Phase III Cell and Gene Therapy Developments, through January 2022

Orphan Drug, Fast Track, Breakthrough Designations

Table 3-6: Orphan Drug, Fast Track and Breakthrough Designations for Dermatology Cell and Gene Therapies in Development (Phase I through III), through January 2022

MARKET BREAKDOWN OF CELL AND GENE THERAPIES

Table 3-7: Dermatology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031 ($ millions)
Figure 3-3: Dermatology Cell and Gene Therapy Market Distribution by Product Type, 2021 (%) Dermatology Cell and Gene Therapy Market by Indication
Table 3-8: Dermatology Cell and Gene Therapy Market by General Indication, Estimated 2021, Projected 2031 ($ millions)

REGIONAL MARKET SUMMARY

Figure 3-4: Dermatology Cell and Gene Therapy Approvals by Country/Region, through 2021
Table 3-9: Dermatology Cell and Gene Therapy Market by Country/Region, Estimated 2021, Projected 2031 ($ millions)
Figure: 3-5: Dermatology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031 ($ millions)

COMPETITOR SUMMARY

Table 3-10: Dermatology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)

CHAPTER 4: CELL AND GENE THERAPY MARKETS IN CARDIOVASCULAR AND BLOOD DISORDERS
OVERVIEW

Cardiovascular Disease
Selected Blood Disorders

MARKET OUTLOOK

Figure 4-1: Cell and Gene Therapy Markets in Cardiovascular and Blood Disorders, 2021-2031, ($ millions)

PRINCIPAL PRODUCTS

Collategene
Hearticellgram
HeartSheet
Leqvio
Neovasculgen
Stempeucel
Zynteglo
Cord Blood Products
Table 4-1: Selected Cell and Gene Therapy in Cardiovascular and Blood Disorders
Figure 4-2: Cardiovascular and Blood Disorders Cell and Gene Therapy Approvals by Year, through 2021

TRENDS IN RESEARCH AND DEVELOPMENT

Table 4-2: Cardiovascular and Blood Disorders Cell and Gene Therapies in Development by Phase, January 2022 Data
Table 4-3: Cardiovascular and Blood Disorders Cell and Gene Therapies in Development by Method, January 2022 Data

Phase III Development

Table 4-4: Select Cardiovascular and Blood Disorder Phase III Cell and Gene Therapy
Developments, through January 2022

Orphan Drug, Fast Track, Breakthrough Designations

Table 4-5: Orphan Drug, Fast Track and Breakthrough Designations for Cardiovascular and Blood
Disorder Cell and Gene Therapies in Development (Phase I through III), through January 2022

MARKET BREAKDOWN OF CELL AND GENE THERAPIES

Table 4-6: Cardiovascular and Blood Disorders Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031 ($ millions)
Figure 4-3: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Distribution by Product Type, 2021 (%)

Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Indication

Table 4-7: Cardiovascular and Blood Disorders Cell and Gene Therapy Market by General Indication, Estimated 2021 and Projected 2031($ millions)

REGIONAL MARKET SUMMARY

Figure 4-4: Cardiovascular and Blood Disorders Cell and Gene Therapy Approvals by Country/Region, through 2021
Table 4-8: Cardiovascular and Blood Disorders Cell and Gene Therapy Market by Country/Region, Estimated 2021 and Projected 2031($ millions)
Figure: 4-5: Cardiovascular and Blood Disorders Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031($ millions)

COMPETITOR SUMMARY

CHAPTER 5: CELL AND GENE THERAPY MARKETS IN ONCOLOGY
OVERVIEW

Biochemistry of Cancer Cells

CAUSES OF CANCER GROWTH

Environmental Factors, DNA, RNA
Table 5-1: Virus Association with Human Cancer
Cellular Oncogenes
Tumor Suppressor Genes

GLOBAL CANCER BURDEN

Figure 5-1: Estimated Number of New Cases from 2020 to 2040, Both Sexes, Age 0-85+, All Cancers
Figure 5-2: Incidence of Cancer by Type, 2020
Figure 5-3: Distribution of Cancer Incidence by Type, 2020

MARKET OUTLOOK

Figure 5-4: Cell and Gene Therapy Markets in Oncology, 2021-2031 ($ millions)

PRINCIPAL PRODUCTS

Abecma
APCeden
Breyanzi
CreaVax-RCC
Gendicine
Imlygic
Immuncell-LC
Kymriah
Provenge
Tecartus
Yescarta
Table 5-2: Cell and Gene Therapy in Oncology
Figure 5-5: Oncology Cell and Gene Therapy Approvals by Year, through 2021

TRENDS IN RESEARCH AND DEVELOPMENT

Table 5-3: Oncology Cell and Gene Therapies in Development by Phase, January 2022 Data
Table 5-4: Oncology Cell and Gene Therapies in Development by Method, January 2022 Data
Figure 5-6: Oncology Cell and Gene Therapy Development by Cancer Type, January 2022 Data (Phase I through Phase III)

Phase III Development

Table 5-5: Select Oncology Phase III Cell and Gene Therapy Developments, through January 2022

Orphan Drug, Fast Track, Breakthrough Designations

Table 5-6: Orphan Drug, Fast Track and Breakthrough Designations for Oncology Cell and Gene
Therapies in Development (Phase I through III), FDA Reported, through March 2020

MARKET BREAKDOWN OF CELL AND GENE THERAPIES

Table 5-7: Oncology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031 ($ millions)
Figure 5-7: Oncology Cell and Gene Therapy Market Distribution by Product Type, 2021 (%)

Oncology Cell and Gene Therapy Market by Cancer Type

Table 5-8: Oncology Cell and Gene Therapy Market by Cancer Type, Estimated 2021 and Projected 2031 ($ millions)
Figure 5-8: Oncology Cell and Gene Therapy Market by General Indication (leukemia, lymphoma, undefined blood cancer, prostate cancer, melanoma, multiple myeloma, other cancers), Estimated 2021 (%)

REGIONAL MARKET SUMMARY

Figure 5-9: Oncology Cell and Gene Therapy Approvals by Country/Region, through 2021
Table 5-9: Oncology Cell and Gene Therapy Market by Country/Region, Estimated 2021 and Projected 2031 ($ millions)
Figure: 5-10: Oncology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031 ($ millions)

COMPETITOR SUMMARY

Table 5-10: Oncology Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)

CHAPTER 6: CELL AND GENE THERAPY MARKETS IN OPHTHALMIC CONDITIONS
OVERVIEW
MARKET OUTLOOK

Figure 6-1: Cell and Gene Therapy Markets in Ophthalmic Conditions, 2021-2031 ($ millions)

PRINCIPAL PRODUCTS
Holoclar
Luxturna

Table 6-1: Cell and Gene Therapy in Ophthalmic Conditions

TRENDS IN RESEARCH AND DEVELOPMENT

Table 6-2: Ophthalmology Cell and Gene Therapies in Development by Phase, January 2022 Data
Table 6-3: Ophthalmology Cell and Gene Therapies in Development by Method, January 2022
Data

Phase III Development

Table 6-4: Select Ophthalmology Phase III Cell and Gene Therapy Developments, through January 2022

Orphan Drug, Fast Track, Breakthrough Designations

Table 6-5: Orphan Drug, Fast Track and Breakthrough Designations for Ophthalmology Cell and Gene Therapies in Development (Phase I through III), FDA Reported, through January 2022

MARKET BREAKDOWN OF CELL AND GENE THERAPIES

Table 6-6: Ophthalmology Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031 ($ millions)
Figure 6-2: Ophthalmology Cell and Gene Therapy Market Distribution by Product Type, 2021 (%)

REGIONAL MARKET SUMMARY

Table 6-7: Ophthalmology Cell and Gene Therapy Market by Country/Region, Estimated 2021 and Projected 2031 ($ millions)
Figure: 6-3: Ophthalmology Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031 ($ millions)

COMPETITOR SUMMARY

CHAPTER 7: CELL AND GENE THERAPY MARKETS IN MUSCULOSKELETAL CONDITIONS AND DISORDERS
OVERVIEW
MARKET OUTLOOK

Figure 7-1: Cell and Gene Therapy Markets in Musculoskeletal Conditions and Disorders, 20212031 ($ millions)

PRINCIPAL PRODUCTS

AlloStem
BIO4
Carticel
Cartiform
CartiLife
Cartistem
Chondron
JACC
MACI
Ortho-ACI and Ortho-ATI
Ossron
Osteocel and Osteoplus
Spherox
Trinity Elite and Trinity Evolution
Table 7-1: Cell and Gene Therapy in Musculoskeletal Diseases and Disorders
Figure 7-2: Musculoskeletal Cell and Gene Therapy Approvals by Year or Year Range, through 2021

TRENDS IN RESEARCH AND DEVELOPMENT

Table 7-2: Musculoskeletal Cell and Gene Therapies in Development by Phase, January 2022 Data
Table 7-3: Musculoskeletal Cell and Gene Therapies in Development by Method, January 2022
Data

Phase III Development

Table 7-4: Select Musculoskeletal Phase III Cell and Gene Therapy Developments, through January 2022

MARKET BREAKDOWN OF CELL AND GENE THERAPIES

Table 7-5: Musculoskeletal Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031 ($ millions)

Musculoskeletal Cell and Gene Therapy Market by Indication

Table 7-6: Musculoskeletal Cell and Gene Therapy Market by General Indication, Estimated 2013 and Projected 2031($ millions)
Figure 7-3: Musculoskeletal Cell and Gene Therapy Market by General Indication (cartilage treatment, bone treatment and other indications), Estimated 2021 (%)

REGIONAL MARKET SUMMARY

Figure 7-4: Musculoskeletal Cell and Gene Therapy Approvals by Country/Region, through 2021
Table 7-7: Musculoskeletal Cell and Gene Therapy Market by Country/Region, Estimated 20 and Projected 2031 ($ millions)
Figure: 7-5: Musculoskeletal Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031($ millions)

COMPETITOR SUMMARY

Table 7-8: Musculoskeletal Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)

CHAPTER 8: CELL AND GENE THERAPY MARKETS IN NEUROLOGICAL-RELATED DISORDERS
OVERVIEW
MARKET OUTLOOK

Figure 8-1: Cell and Gene Therapy Markets in Neurological-Related Conditions, 2021-2031, ($ millions)

PRINCIPAL PRODUCTS

Libmeldy
NeuroNata-R
Onpattro
SKYSONA
Stemirac
Zolgensma
Table 8-1: Cell and Gene Therapy in Neurological Diseases and Disorders

TRENDS IN RESEARCH AND DEVELOPMENT

Phase III Development

Table 8-2: Select Neurological Phase III Cell and Gene Therapy Developments, through January 2022

Orphan Drug, Fast Track, Breakthrough Designations

Table 8-3: Orphan Drug, Fast Track and Breakthrough Designations for Neurological Cell and Gene
Therapies in Development (Phase I through III), FDA Reported, through January 2022

MARKET BREAKDOWN OF CELL AND GENE THERAPIES

Table 8-4: Neurological Conditions Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031($ millions)
Figure 8-2: Neurological Conditions Cell and Gene Therapy Market Distribution by Product Type, 2021 (%)

REGIONAL MARKET SUMMARY

Table 8-5: Neurological Conditions Cell and Gene Therapy Market by Country/Region, Estimated 2021 and Projected 2031($ millions)
Figure 8-3: Neurological Conditions Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031($ millions)

COMPETITOR SUMMARY

Table 8-6: Neurological Conditions Cell and Gene Therapy Competitor Market Share, Reported and Estimated 2021 ($ millions)

CHAPTER 9: CELL AND GENE THERAPY MARKETS IN OTHER CONDITIONS
OVERVIEW
MARKET OUTLOOK

Figure 9-1: Cell and Gene Therapy Markets in Other Conditions, 2021-2031, ($ millions)

PRINCIPAL PRODUCTS

Alofisel
Cupistem
Givlaari
Glybera
Oxlumo
Rethymic
Ryplazim
Strimvelis
Temcell/Prochymal/Ryoncil
Table 9-1: Cell and Gene Therapy in Other Diseases and Disorders

TRENDS IN RESEARCH AND DEVELOPMENT
MARKET BREAKDOWN OF CELL AND GENE THERAPIES

Table 9-2: Other Conditions Cell and Gene Therapy Markets by Product Type, Estimated 2021 and Projected 2031($ millions)
Figure 9-2: Other Conditions Cell and Gene Therapy Market Distribution by Product Type, 2021(%)

REGIONAL MARKET SUMMARY

Table 9-3: Other Conditions Cell and Gene Therapy Market by Country/Region, Estimated 20 and Projected 2031($ millions)
Figure 9-3: Other Conditions Cell and Gene Therapy Market Summary by Geographic Region, Estimated 2021 and Projected 2031($ millions)

COMPETITOR SUMMARY

CHAPTER 10: CELL AND GENE THERAPY MARKET REVIEW
MARKET INFLUENCES
Global Demographics

Table 10-1: Global Population, through 2050 (population in millions)
Figure 10-1: Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050

Cost Containment

Table 10-2: Cost Comparisons for Selected Commercialized Cell and Gene Therapies

CELL AND GENE THERAPY AND VIRAL VECTOR SHORTAGES
GLOBAL MARKET SUMMARY.

Table 10-3: Cell and Gene Therapy Market Summary by Product Segment, 2021-2031 ($ millions)
Figure 10-2: Cell and Gene Therapy Market Summary by Product Segment, 2021-2031
Figure 10-3: Cell and Gene Therapy Market, Distribution of Sales by Product Segment, 2021

CELL VS. GENE THERAPY MARKETS

Table 10-4: Cell and Gene Therapy Market Summary by Method, 2021-2031 ($ millions)
Figure 10-4: Cell and Gene Therapy Market, Distribution of Sales by Method, 2021

REGIONAL MARKET OVERVIEW

Table 10-5: Cell and Gene Therapy Market Summary by Geographical Region, 2021-2031 ($ millions)

UNITED STATES

Table 10-6: Cell and Gene Therapy Market Summary for United States by Product Segment, 20212031 ($ millions)
Figure 10-5: U.S. Cell and Gene Therapy Market, Distribution by Product Segment (dermatology, cardiovascular-blood, oncology, ophthalmology, musculoskeletal, neurology, other conditions), 2021 (%)
Table 10-7: Major Cell and Gene Therapy Product Approvals, FDA

EUROPE/EUROPEAN UNION

Table 10-8: Cell and Gene Therapy Market Summary for Europe/European Union by Product Segment, 2021-2031 ($ millions)
Figure 10-6: Europe Cell and Gene Therapy Market, Distribution by Product Segment (dermatology, cardiovascular-blood, oncology, ophthalmology, musculoskeletal, neurology, other conditions), 2021 (%)
Table 10-9: Major Cell and Gene Therapy Approvals by EMA

OTHER COUNTRIES

Table 10-10: Cell and Gene Therapy Market Summary for Other Countries by Product Segment, 2021-2031 ($ millions)
Figure 10-7: Other Countries Cell and Gene Therapy Market, Distribution by Product Segment (dermatology, cardiovascular-blood, oncology, ophthalmology, musculoskeletal, neurology, other conditions), 2021 (%)
Table 10-11: Select Major Cell and Gene Therapy Approvals by Various Regulatory Authorities

COMPETITOR RANKING IN CELL AND GENE THERAPY MARKETS

Table 10-12: Estimated Cell and Gene Therapy Sales by Leading Competitor, 2021 Sales ($ millions)
Figure 10-8: Cell and Gene Therapy Market Share Estimates, 2021

CHAPTER 11: MARKET PARTICIPANTS
LEADING INFLUENCERS
ADVAXIS, INC. (BIOSIGHT THERAPEUTICS)

Table 11-1: Advaxis Corporate Summary
Company Summary
Products

ALLOSOURCE

Table 11-2: AlloSource Corporate Summary
Company Summary
Products

ALNYLAM PHARMACEUTICALS, INC.

Table 11-3: Alnylam Pharmaceuticals Corporate Summary
Company Summary
Products

AMGEN

Table 11-4: Amgen Corporate Summary
Company Summary
Products

ANGES INC.

Table 11-5: AnGes Corporate Summary
Company Summary
Products

ANTEROGEN CO LTD.

Table 11-6: Anterogen Corporate Summary
Company Summary
Products

ATARA BIOTHERAPEUTICS

Table 11-7: Atara Biotherapeutics Corporate Summary
Company Summary
Products

ATHERSYS, INC

Table 11-8: Athersys Corporate Summary
Company Summary
Products

BIOCARDIA

Table 11-9: BioCardia Summary
Company Summary
Products

BIOGEN, INC.

Table 11-10: Biogen Corporate Summary
Company Summary
Products

BIOMARIN PHARMACEUTICALS

Table 11-11: BioMarin Pharmaceuticals Corporate Summary
Company Summary
Products

BLUEBIRD BIO, INC.

Table 11-12: bluebird bio Corporate Summary
Company Summary
Products

BRAINSTORM CELL THERAPEUTICS

Table 11-13: BrainStorm Cell Therapeutics Corporate Summary
Company Summary
Products

BRISTOL-MYERS SQUIBB

Table 11-14: Bristol-Myers Squibb Corporate Summary
Company Summary
Products

CALADRIUS BIOSCIENCES

Table 11-15: Caladrius Biosciences Corporate Summary
Company Summary
Products

CANDEL THERAPEUTICS

Table 11-16: Candel Therapeutics Corporate Summary
Company Summary
Products

CASTLE CREEK BIOSCIENCES

Table 11-17: Castle Creek Corporate Summary
Company Summary
Products

CELYAD ONCOLOGY

Table 11-18: Celyad Oncology Corporate Summary
Company Summary
Products

COOK MYOSITE, INC

Table 11-19: Cook Myosite Corporate Summary
Company Summary
Products

CYTORI THERAPEUTICS, INC

Table 11-20: Cytori Therapeutics Corporate Summary
Company Summary
Products

DENDREON PHARMACEUTICALS LLC

Table 11-21: Dendreon Corporate Summary
Company Summary
Products

FERGENE, INC/FERRING PHARMACEUTICALS

Table 11-22: FerGene Corporate Summary
Company Summary
Products

GAMIDA CELL LTD.

Table 11-23: Gamida Cell Corporate Summary
Company Summary
Products

GENSIGHT BIOLOGICS S.A.

Table 11-24: GenSight Biologics Corporate Summary
Company Summary
Products

GILEAD SCIENCES, INC.

Table 11-25: Gilead Sciences Corporate Summary
Company Summary
Products

GRADALIS, INC

Table 11-26: Gradalis Corporate Summary
Company Summary
Products

HELIXMITH

Table 11-27: Helixmith Corporate Summary
Company Summary
Products

INOVIO PHARMACEUTICALS, INC.

Table 11-28: Inovio Pharmaceuticals Corporate Summary
Company Summary
Products

KIADIS PHARMA B.V. (SANOFI)

Table 11-29: Kiadis Pharma Corporate Summary
Company Summary
Products

MEDEOR THERAPEUTICS

Table 11-30: Medeor Therapeutics Corporate Summary
Company Summary
Products

MEDIPOST CO, LTD.

Table 11-31: MEDIPOST Corporate Summary
Company Summary
Products

MEIRAGTX

Table 11-32: MeiraGTxCorporate Summary
Company Summary
Products

MERCK & CO., INC.

Table 11-33: Merck & Co. Corporate Summary
Company Summary
Products

MESOBLAST LTD.

Table 11-34: Mesoblast Corporate Summary
Company Summary
Products

NEUROTECH PHARMACEUTICALS. INC.

Table 11-35: Neurotech Corporate Summary
Company Summary
Products

NORTHWEST BIOTHERAPEUTICS, INC.

Table 11-36: Northwest Biotherapeutics Corporate Summary
Company Summary
Products

NOVARTIS AG

Table 11-37: Novartis Corporate Summary
Company Summary
Products

NUVASIVE BIOLOGICS

Table 11-38: NuVasive Biologics Corporate Summary
Company Summary
Products

ORCHARD THERAPEUTICS

Table 11-39: Orchard Therapeutics Corporate Summary
Company Summary
Products

ORGANOGENESIS

Table 11-40: Organogenesis Corporate Summary
Company Summary
Products

ORTHOFIX

Table 11-41: Orthofix Corporate Summary
Company Summary
Products

OSIRIS THERAPEUTICS, INC.( PART OF SMITH & NEPHEW)

Table 11-42: Osiris Corporate Summary
Company Summary
Products

PHARMICELL

Table 11-43: Pharmicell Corporate Summary
Company Summary
Products

PLURISTEM THERAPEUTICS, INC.

Table 11-44: Pluristem Therapeutics Corporate Summary
Company Summary
Products

SANGAMO THERAPEUTICS

Table 11-45: Sangamo Therapeutics Corporate Summary
Company Summary
Products

SANOFI

Table 11-46: Sanofi Corporate Summary
Company Summary
Products

SOTIO A.S

Table 11-47: Sotio Corporate Summary
Company Summary
Products

SPARK THERAPEUTICS

Table 11-48: Spark Therapeutics Corporate Summary
Company Summary
Products

TESSA THERAPEUTICS, LTD.

Table 11-49: Tessa Therapeutics Corporate Summary
Company Summary
Products

UNIQURE N.V.

Table 11-50: UniQure Corporate Summary
Company Summary
Products

VBL THERAPEUTICS (VASCULAR BIOGENICS LTD.)

Table 11-51: VBL Therapeutics Corporate Summary
Company Summary
Products

VERICEL CORPORATION

Table 11-52: Vericel Corporate Summary
Company Summary
Products

Companies Mentioned

Advaxis, Inc. (Biosight Therapeutics)
Allosource
Alnylam Pharmaceuticals, Inc.
Amgen
Anges Inc.
Anterogen Co Ltd.
Atara Biotherapeutics
Athersys, Inc
Biocardia
Biogen, Inc.
Biomarin Pharmaceuticals
Bluebird Bio, Inc.
Brainstorm Cell Therapeutics
Bristol-Myers Squibb
Caladrius Biosciences
Candel Therapeutics
Castle Creek Biosciences
Celyad Oncology
Cook Myosite, Inc
Cytori Therapeutics, Inc
Dendreon Pharmaceuticals LLC
Fergene, Inc/Ferring Pharmaceuticals
Gamida Cell Ltd.
Gensight Biologics S.A.
Gilead Sciences, Inc.
Gradalis, Inc
Helixmith
Inovio Pharmaceuticals, Inc.
Kiadis Pharma B.V. (Sanofi)
Medeor Therapeutics
Medipost Co, Ltd.
Meiragtx
Merck & Co. Inc.
Mesoblast Ltd.
Neurotech Pharmaceuticals. Inc.
Northwest Biotherapeutics, Inc.
Novartis AG
Nuvasive Biologics
Orchard Therapeutics
Organogenesis
Orthofix
Osiris Therapeutics, Inc.( Part of Smith & Nephew)
Pharmicell
Pluristem Therapeutics, Inc.
Sangamo Therapeutics
Sanofi
Sotio A.S
Spark Therapeutics
Tessa Therapeutics, Ltd.
Uniqure N.V.
VBL Therapeutics (Vascular Biogenics Ltd.)
Vericel Corporation

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - Lifetime	The product can be accessed through a secure website. Username and password will be sent via email. The access never expires.	This is a single user license, allowing one user access to the product.	€5345EUR$6,000USD£4,651GBP
1 - 10 USER LICENSE PDF	The product is a PDF.	This is a 1-10 user license, allowing up to ten users have access to the product.	€8017EUR$9,000USD£6,976GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€10690EUR$12,000USD£9,302GBP

Scope

The following conditions/disorders are covered:

Dermatology, including:

Cardiovascular and Blood Disorders, including:

Oncology, including:

Ophthalmic Conditions, including:

Musculoskeletal Conditions and Disorders, including:

Other Conditions, including:

Table of Contents

Companies Mentioned

Related Topics

Related Reports

Cell And Gene Therapy Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III), By Indication (Oncology, Cardiology, CNS, Musculoskeletal, Infectious Diseases), By Region, And Segment Forecasts, 2025 - 2033

Cell and Gene Therapy Clinical Trial Services - Global Strategic Business Report

Cell Sheet-based Gene Therapy Market - A Global and Regional Analysis: Focus on Technology Type, Cell-sheet Type, Source Type, Application Type, End User, and Regional Analysis - Analysis and Forecast, 2025-2035

Cell & Gene Therapy Contract Research Organizations Market Size, Share & Trends Analysis Report By Type (Drug Discovery, Preclinical, Clinical), By Service (Regulatory Strategy, Clinical Monitoring), By Indication, By Modality, By Region, And Segment Forecasts, 2025 - 2033

Gene Therapy Clinical Trial Services - Global Strategic Business Report